ondasdechoque.org
PT-BR

Diabetic ulcers: shockwaves versus hyperbaric oxygen · Randomized trial · 2011

How does shockwave compare with hyperbaric oxygen for diabetic foot ulcers?

In this trial, ulcers closed completely in 24 of 44 feet after six shockwave sessions, compared with 10 of 40 feet after a course of hyperbaric oxygen (breathing oxygen in a pressure chamber). Blood flow in the foot also rose after shockwave.

people with diabetic foot ulcers
88
shockwave sessions over 3 weeks
6
hyperbaric oxygen sessions in the other group
40

Good to know: Results were counted per foot (84 feet in 77 people), and a few of the report's counts don't match its percentages.

Wang CJ, Wu RW, Yang YJ Diabetes Res Clin Pract, 2011 · Read the paper ↗

How this study worked

Shockwave43 peopleHyperbaric oxygen45 people
People were assigned to the groups by lot. Each dot is one person.

The treatment

Shockwave

Shockwave, twice a week for 3 weeks

ShockwavesThe paper doesn’t say whether radial or focused
Pulses
500 per session · at least; more for bigger wounds (8 per cm² of wound plus a 1 cm border)
Strength
0.23mJ/mm² setting E2, as printed · 4 per second
Numbing
None
Device
dermaPACE
Everyone also got
Pressure relief for the foot, saline cleaning, silver sulfadiazine cream and antibiotics when needed

Compared with: Hyperbaric oxygen: 40 sessions of 90 minutes breathing oxygen in a pressure chamber, with the same wound care

Settings are what each study used, not a prescription.

Who took part

88 people with long-standing diabetic foot ulcers: 43 had shockwave and 45 hyperbaric oxygen; 77 people (84 feet) were analysed.

hollow squares: no final score

Shockwave39 of 43 measured
Hyperbaric oxygen38 of 45 measured
77 of 88 people (88%) had a final score.

Side effects

No complications from shockwave were reported. Four people in the oxygen group had ear or sinus pain from the pressure, which settled. Two people in the shockwave group died of causes judged unrelated.

All the numbers and the full appraisal
FROM THE FULL PAPER

What the full paper reports.

88 allocated patients, 43 ESWT/45 HBOT; 77 patients with 84 feet analyzed after 4/7 losses, respectively.

Shockwave treatment43randomized

Participant counts; outcome-specific denominators remain in each panel.

Hyperbaric oxygen45randomized

Participant counts; outcome-specific denominators remain in each panel.

Reported complete closure, conflicting percentage1 reported outcome
01
After first treatment course

Reported complete closure, conflicting percentage

Reported complete closure, conflicting percentage affected feet

REPORTED COMPARISON TESTp = 0.003

Between reported groups

Source-reported comparison

Complete closure: Table 3 prints 57% (24 of 44 feet) with ESWT versus 25% (10 of 40 feet) with HBOT. Numbers are as printed: 24/44 is 54.5%, not 57% (25/44 would give 57%), and the ESWT first-course categories add up to 43 of 44 feet. Foot denominators, not participants.

Analysis details and source

Complete closure: Table 3 prints 57% (24 of 44 feet) with ESWT versus 25% (10 of 40 feet) with HBOT. Numbers are as printed: 24/44 is 54.5%, not 57% (25/44 would give 57%), and the ESWT first-course categories add up to 43 of 44 feet. Foot denominators, not participants.

At least 50% improvement1 reported outcome
02
After first course

At least 50% improvement

At least 50% improvement affected feet

REPORTED COMPARISON TESTp = 0.071

Between reported groups

Source-reported comparison

Improvement: 14/44 ESWT feet versus 6/40 HBOT feet. Not statistically significant; distinct from complete closure.

Analysis details and source

Improvement: 14/44 ESWT feet versus 6/40 HBOT feet. Not statistically significant; distinct from complete closure.

Complete closure after selected second course1 reported outcome
03
Second course

Complete closure after selected second course

Complete closure after selected second course affected feet

REPORTED COMPARISON TESTp = 0.005

Between reported groups

Source-reported comparison

Second-course closure: 7/14 selected ESWT ulcers versus 1/17 selected HBOT ulcers. Selected responding but unhealed ulcers; no new randomization.

Analysis details and source

Second-course closure: 7/14 selected ESWT ulcers versus 1/17 selected HBOT ulcers. Selected responding but unhealed ulcers; no new randomization.

Doppler perfusion1 reported outcome
04
Before and after treatment

Doppler perfusion

Doppler perfusion arbitrary perfusion units; feet

Table 4 reports ESWT perfusion 0.48 (range 0.32–0.64) before and 0.61 (0.40–0.79) after treatment, within-group p<.001; HBOT 0.59 (0.50–0.63) and 0.50 (0.11–0.53), p=.916. Between-group p=.245 before and p=.002 after. These are source-reported values in arbitrary perfusion units for 44 versus 40 feet, not independent people; ranges are not standard deviations.

Analysis details and source

Table 4 reports ESWT perfusion 0.48 (range 0.32–0.64) before and 0.61 (0.40–0.79) after treatment, within-group p<.001; HBOT 0.59 (0.50–0.63) and 0.50 (0.11–0.53), p=.916. Between-group p=.245 before and p=.002 after. These are source-reported values in arbitrary perfusion units for 44 versus 40 feet, not independent people; ranges are not standard deviations.

Unchanged and partial responses1 reported outcome
05
First and selected second courses

Unchanged and partial responses

Unchanged and partial responses affected feet

After the first course, 5/44 ESWT feet and 24/40 HBOT feet were unchanged (p<.001); none worsened. In the selected second-course subgroups, ≥50% improvement occurred in 6/14 versus 8/17 feet (p=.815), and no change in 1/14 versus 8/17 (p=.015); none worsened. The second course was discretionary, not a new randomized comparison.

Analysis details and source

After the first course, 5/44 ESWT feet and 24/40 HBOT feet were unchanged (p<.001); none worsened. In the selected second-course subgroups, ≥50% improvement occurred in 6/14 versus 8/17 feet (p=.815), and no change in 1/14 versus 8/17 (p=.015); none worsened. The second course was discretionary, not a new randomized comparison.

How treatment was delivered
Reported protocol

dermaPACE, E2 printed 0.23 mJ/mm², 4 Hz, impulses=area expanded 1 cm× 8, minimum 500; twice weekly× 3 weeks, no anesthesia. HBOT 2.5 ATA× 90 min× 40; offloading, saline, silver sulfadiazine±antibiotics.

HARMS & TOLERABILITY

Four HBOT patients had middle-ear barotrauma/sinus pain resolving with decompression; no systemic/local ESWT complication reported. Two ESWT-arm deaths were classified unrelated and excluded.

LIMITS OF THE ANALYSIS

Open-label, predictable odd/even assignment; 11 exclusions and foot-level analysis without clustering adjustment. Table 3 ESWT categories sum 43, not 44, and 24/44 is not 57%. Second courses were clinician-selected, not rerandomized. Sanuwave supplied device/applicators; Wang advisory relationship disclosed. Funding: Chang Gung research grant CMRPG880221.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Open-label, predictable odd/even assignment; 11 exclusions and foot-level analysis without clustering adjustment. Table 3 ESWT categories sum 43, not 44, and 24/44 is not 57%. Second courses were clinician-selected, not rerandomized. Sanuwave supplied device/applicators; Wang advisory relationship disclosed. Funding: Chang Gung research grant CMRPG880221.
Research review

Source-linked critical reading

Randomized trials

Reading depthMaterial consulted
Technical source record

Full source read: body, methods, results, all tables and figure captions, discussion and disclosures. The article lists no supplementary material.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Comparative trial assigning 88 patients by predictable odd/even numbers; 77 people with 84 feet entered the reported analysis. Allocation was described as randomized but concealment is doubtful.

Participants and setting

88 allocated patients, 43 ESWT/45 HBOT; 77 patients with 84 feet analyzed after 4/7 losses, respectively.

Treatment delivered

Six ESWT sessions over 3 weeks, with offloading and local wound care.

What was compared

Forty HBOT sessions, 2.5 ATA, 90 min, five per week; same wound care.

Outcomes and timing

The extracted panels retain the original outcome units and assessment times. Table 3 reports 57% (24/44) completely healed after ESWT and 25% (10/40) after HBOT, p=.003; numerator and percentage conflict. ≥50% improvement 14/44 versus 6/40, p=.071; unchanged 5/44 versus 24/40. Perfusion post-treatment 0.61 versus 0.50, p=.002.

Results in context

Table 3 reports 57% (24/44) completely healed after ESWT and 25% (10/40) after HBOT, p=.003; numerator and percentage conflict. ≥50% improvement 14/44 versus 6/40, p=.071; unchanged 5/44 versus 24/40. Perfusion post-treatment 0.61 versus 0.50, p=.002.

Harms and tolerability

Four HBOT patients had middle-ear barotrauma/sinus pain resolving with decompression; no systemic/local ESWT complication reported. Two ESWT-arm deaths were classified unrelated and excluded.

Limits and disclosures

Open-label, predictable odd/even assignment; 11 exclusions and foot-level analysis without clustering adjustment. Table 3 ESWT categories sum 43, not 44, and 24/44 is not 57%. Second courses were clinician-selected, not rerandomized. Sanuwave supplied device/applicators; Wang advisory relationship disclosed. Funding: Chang Gung research grant CMRPG880221.

Clinical applicability

Suggestive comparison with HBOT, but source discrepancies and attrition prevent a clean precision estimate or general claim of superiority.

What a next study should resolve

Use concealed randomization, retain deaths and withdrawals in patient accounting, reconcile foot-level closure counts and prespecify any second treatment course with a separate randomized comparison.

THE ORIGINAL SOURCE

Read the original article.

Treatment of diabetic foot ulcers: A comparative study of extracorporeal shockwave therapy and hyperbaric oxygen therapy

Wang CJ, Wu RW, Yang YJ. · Diabetes Res Clin Pract · 2011

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →